SG10201906900QA - Cardiovascular risk event prediction and uses thereof - Google Patents

Cardiovascular risk event prediction and uses thereof

Info

Publication number
SG10201906900QA
SG10201906900QA SG10201906900QA SG10201906900QA SG10201906900QA SG 10201906900Q A SG10201906900Q A SG 10201906900QA SG 10201906900Q A SG10201906900Q A SG 10201906900QA SG 10201906900Q A SG10201906900Q A SG 10201906900QA SG 10201906900Q A SG10201906900Q A SG 10201906900QA
Authority
SG
Singapore
Prior art keywords
cardiovascular risk
risk event
event prediction
hbp9bc9hqi
h9hd9e9dl
Prior art date
Application number
SG10201906900QA
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of SG10201906900QA publication Critical patent/SG10201906900QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

$%&'(#)"*+#$$&),-(-./$-%&"/&'.#.%*)-)/1-$-'2 34567386 49:;<=>?=@A;?BC:D@AD?E9F?@A=?<G?HB@A@I@B?;@A<HD>9B@ J:=BC??E<KL<B9:H:J=9@>:J< F<=<D9:E<@FLK<=M8NO?E?HBP9BC9HQI?<=@<=?D9@FK:@?DR6C ?S9:;<=>?=@BC<BF<HS?L@?D<K:H?:= 9HE<=9:L@F:;S9H<B9:H@B:?E<KL<B?=9@>:J<8N?E?HBP9BC9H QI?<=@R6C?;?BC:D@<=?T=:E9D?D J:=?E<KL<B9HG=9@>:J<8Nÿ?E?HBP9BC9HQI?<=@9H<H9HD9E9DL <KAPC?=?BC?;?BC:D@9HFKLD? D?B?FB9HGA9H<S9:K:G9F<K@<;TK?J=:;<H9HD9E9DL<KA<BK?< @B:H?S9:;<=>?=E<KL?ABC?S9:;<=>?= S?9HG@?K?FB?DJ=:;<G=:LT:JS9:;<=>?=@R UVWX3 85
SG10201906900QA 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof SG10201906900QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30

Publications (1)

Publication Number Publication Date
SG10201906900QA true SG10201906900QA (en) 2019-09-27

Family

ID=47993164

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201400904SA SG11201400904SA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof
SG10201906900QA SG10201906900QA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof
SG10201607331WA SG10201607331WA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201400904SA SG11201400904SA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201607331WA SG10201607331WA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Country Status (17)

Country Link
US (3) US20130085079A1 (en)
EP (1) EP2761289B1 (en)
JP (3) JP6652781B2 (en)
KR (2) KR102248900B1 (en)
CN (4) CN107102151A (en)
AU (1) AU2013202112B9 (en)
BR (2) BR112014007214B1 (en)
CA (2) CA2847903C (en)
ES (1) ES2777002T3 (en)
HK (1) HK1247666A1 (en)
IL (1) IL231387A (en)
IN (1) IN2014CN01970A (en)
MX (2) MX2014003153A (en)
RU (1) RU2651708C2 (en)
SG (3) SG11201400904SA (en)
WO (1) WO2013049674A1 (en)
ZA (1) ZA201401778B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
EP2576826B1 (en) * 2010-06-07 2014-09-17 King's College London Methods and means for predicting or diagnosing type ii diabetes or myocardial infarction based on micro rna detection.
EP2591357A4 (en) 2010-07-09 2014-01-01 Somalogic Inc Lung cancer biomarkers and uses thereof
KR101857462B1 (en) 2010-08-13 2018-05-14 소마로직, 인크. Pancreatic cancer biomarkers and uses thereof
JP6018096B2 (en) 2011-03-10 2016-11-02 ソマロジック・インコーポレーテッド Aptamers for Clostridium difficile diagnosis
BR112014007214B1 (en) * 2011-09-30 2022-08-16 Somalogic Operating Co., Inc METHOD FOR DETERMINING THE PROBABILITY THAT AN INDIVIDUAL IS AT HIGH RISK OF A CARDIOVASCULAR EVENT, METHOD FOR ASSESSING THE RISK OF A FUTURE CARDIOVASCULAR EVENT AND COMPUTER-IMPLEMENTED METHOD FOR ASSESSING THE RISK OF A CARDIOVASCULAR EVENT
JP6198047B2 (en) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 Coronary artery disease test kit
KR102348283B1 (en) * 2013-09-24 2022-01-10 소마로직, 인크. Multiaptamer target detection
US20170138961A1 (en) * 2014-03-21 2017-05-18 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of the risk for development of a cardiovascular disorder
CA2949731A1 (en) * 2014-06-05 2015-12-10 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
CA2961340C (en) * 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017011329A1 (en) * 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
RU2602451C1 (en) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Diagnostic technique for genetic predisposition to ischemic stroke development in patients with atrial fibrillation
KR20180105156A (en) * 2016-02-08 2018-09-27 소마로직, 인크. Non-alcoholic fatty liver disease (NAFLD) and nonalcoholic fatty liver disease (NASH) biomarkers and their use
EP3426826A4 (en) * 2016-03-09 2019-09-04 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
EP3440468B1 (en) * 2016-04-06 2021-12-01 Nestle Sa Biomarkers for predicting degree of weight loss
CN108882868B (en) * 2016-04-15 2021-05-18 欧姆龙株式会社 Biological information analysis device, system, and program
CN105907857A (en) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 Molecular marker for artery thrombosis, reagent and application thereof
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
EP3279665B1 (en) * 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
JP7058331B2 (en) * 2017-12-13 2022-04-21 エフ．ホフマン－ラ ロシュ アーゲー Circulating angiopoietin-2 (Ang-2) and insulin-like growth factor binding protein 7 (IGBP7) for stroke prediction
RU2685859C1 (en) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method for prediction of risk of developing ischemic stroke
CN109192250B (en) * 2018-08-01 2021-12-07 华东理工大学 Accelerated simulation method for overcoming rapid migration of surface species in heterogeneous catalysis
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
CN113302498A (en) * 2018-08-22 2021-08-24 豪夫迈·罗氏有限公司 Application of circulating SPON-1 (spinal protein-1) in evaluation of atrial fibrillation
KR102125053B1 (en) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 Composition for detecting cardiovascular disease, and kit comprising the same
MX2021009726A (en) 2019-02-14 2021-09-14 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject.
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
IL302138A (en) * 2020-10-20 2023-06-01 Somalogic Operating Co Inc Cardiovascular event risk prediction
RU2750716C1 (en) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Method for predicting cardiovascular complications in patients with low or moderate cardiovascular risk by assessing their psychological status
US20240060998A1 (en) * 2021-02-01 2024-02-22 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (en) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Method for determining individual profile of total cardiovascular risk factors in patient of working age
WO2023023748A1 (en) * 2021-08-26 2023-03-02 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP2004500100A (en) * 2000-03-06 2004-01-08 スミスクライン・ビーチャム・コーポレイション New compound
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
PT3072978T (en) * 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
AU2005313938A1 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
CN2783324Y (en) * 2005-04-28 2006-05-24 穆海东 Chip reagent box for cardiovascular diseases diagnosis and predicating multiple indes protein
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP1988174B1 (en) * 2006-01-31 2011-10-12 Mitsubishi Chemical Medience Corporation Method for determination of condition of disseminated intravascular coagulation syndrome
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (en) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Method for genetic diagnostics of susceptibility to cardiovascular diseases
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CN101842114A (en) * 2007-08-02 2010-09-22 阿雷斯托生物科学股份有限公司 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010019574A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
ES2795003T3 (en) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarker for the prediction of the first adverse events
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
SG176692A1 (en) * 2009-06-15 2012-01-30 Cardiodx Inc Determination of coronary artery disease risk.
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
WO2011109642A1 (en) * 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
BR112014007214B1 (en) * 2011-09-30 2022-08-16 Somalogic Operating Co., Inc METHOD FOR DETERMINING THE PROBABILITY THAT AN INDIVIDUAL IS AT HIGH RISK OF A CARDIOVASCULAR EVENT, METHOD FOR ASSESSING THE RISK OF A FUTURE CARDIOVASCULAR EVENT AND COMPUTER-IMPLEMENTED METHOD FOR ASSESSING THE RISK OF A CARDIOVASCULAR EVENT
ES2779698T3 (en) * 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Growth differentiation factor 11 (GDF) for the treatment of age-related cardiovascular conditions

Also Published As

Publication number Publication date
US20200166523A1 (en) 2020-05-28
KR20200055804A (en) 2020-05-21
BR112014007214B1 (en) 2022-08-16
EP2761289A4 (en) 2015-08-12
CN103959060A (en) 2014-07-30
ES2777002T3 (en) 2020-08-03
US20130085079A1 (en) 2013-04-04
BR122019023720A2 (en) 2017-04-04
BR122019023720B1 (en) 2023-01-24
AU2013202112A1 (en) 2013-05-02
IN2014CN01970A (en) 2015-05-29
WO2013049674A1 (en) 2013-04-04
CN114518458A (en) 2022-05-20
ZA201401778B (en) 2018-08-25
SG11201400904SA (en) 2014-04-28
MX2020004617A (en) 2020-08-06
JP6546318B2 (en) 2019-07-17
RU2651708C2 (en) 2018-04-23
KR102111624B1 (en) 2020-05-18
CA3074279C (en) 2021-10-19
IL231387A (en) 2017-12-31
JP6652781B2 (en) 2020-02-26
JP6917432B2 (en) 2021-08-11
RU2014110508A (en) 2015-11-10
CN107102151A (en) 2017-08-29
MX2014003153A (en) 2014-04-30
JP2020024216A (en) 2020-02-13
BR112014007214A2 (en) 2017-04-04
AU2013202112B2 (en) 2015-09-24
CN107422126A (en) 2017-12-01
EP2761289A1 (en) 2014-08-06
SG10201607331WA (en) 2016-11-29
CA2847903C (en) 2020-10-27
NZ622118A (en) 2016-01-29
EP2761289B1 (en) 2020-02-12
BR112014007214A8 (en) 2022-07-26
JP2014528576A (en) 2014-10-27
JP2018159713A (en) 2018-10-11
HK1247666A1 (en) 2018-09-28
CA2847903A1 (en) 2013-04-04
CN107422126B (en) 2020-03-27
CA3074279A1 (en) 2013-04-04
AU2013202112B9 (en) 2015-10-22
US20150168423A1 (en) 2015-06-18
KR20140084106A (en) 2014-07-04
IL231387A0 (en) 2014-04-30
BR122019023720A8 (en) 2022-07-26
CN103959060B (en) 2017-05-17
KR102248900B1 (en) 2021-05-07

Similar Documents

Publication Publication Date Title
SG10201906900QA (en) Cardiovascular risk event prediction and uses thereof
ZA202106976B (en) Method for encoding and method for decoding a lut and corresponding devices
AR112588A2 (en) APPARATUS AND METHOD FOR IMAGE PROCESSING
PH12016500079A1 (en) Palette prediction in palette-based video coding
CA3028883C (en) Data encoding and decoding
IN2014CN01827A (en)
EP4307682A3 (en) Video decoding method
MY174583A (en) Signaling quantization matrices for video coding
MY171806A (en) Generating additional merge candidates
WO2013003805A3 (en) Fast encoding method for lossless coding
WO2013009441A3 (en) Scalable video coding using multiple coding technologies
HK1221101A1 (en) Adaptive support for interpolating values of sub-pixels for video coding
MX2012010853A (en) Anti-lrp6 antibodies.
EP2728443A3 (en) Encoding dynamic haptic effects
SG194461A1 (en) Offset type and coefficients signaling method for sample adaptive offset
IN2014MN01592A (en)
EP4250732A3 (en) Motion prediction in video coding
EP2797380A4 (en) Method, entity and system for realizing cluster service
GB201217233D0 (en) Agent matching based on video analysis of customer presentation
EP2748776A4 (en) Network predictive customer service queue management
WO2012005549A3 (en) Methods and apparatuses for encoding and decoding motion vector
WO2013009104A3 (en) Inter prediction method and apparatus for same
ZA201500504B (en) Linear prediction based audio coding using improved probability distribution estimation
EP2577536A4 (en) Methods and compositions for predicting unobserved phenotypes (pup)
WO2014055826A3 (en) Improved architecture for hybrid video codec